The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
The firm said that it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its platform for early detection of recurrent renal cell carcinoma.
Researchers at the University of Birmingham in the UK were awarded £275,000 to develop the new test to measure PSA levels better than conventional tests.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports.
Its first assay for complete blood counting employs lens-free imaging and a platform that uses a silicon chip to execute operations at the microscale level.
The company will receive an upfront $9.3 million to fund a clinical trial for its NGP phenotyping platform and is eligible for an additional $36 million.
IQuity develops tests that use RNA expression data to predict, detect, and monitor disease, as well as stratify patients by severity of disease.
The grants include funding for five new clinical sites, a new metabolomics core, and increased model organism capabilities.
The goal of the project is to develop a strategy that will increase demand for and access to HIV self-testing among at-risk Nigerian youths.